Morphotek has leveraged its platform technology to develop a pipeline of therapeutic antibodies to treat cancer, inflammation and infectious diseases. Through a series of collaborations with leading research institutes, the Company is developing validated disease targets and antibodies that treat targeted disease indications.

Below is a list of the Mophotek’s lead products, their target indications and current collaborators.

Antibody	Target Indication(s)	Collaborator
Farletuzumab	Ovarian cancer Endometrial cancer Renal carcinoma NSCLC Colo-rectal cancer Breast cancer	Ludwig Institute for Cancer Research
MORAb-004	Neovascular disease Cancer	Ludwig Institute for Cancer Research Johns Hopkins University
MORAb-009	Pancreatic cancer Mesothelioma Ovarian cancer Endometrial cancer NSCLC	National Cancer Institute
MORAb-022	Rheumatoid arthritis Multiple Sclerosis Asthma	Morphotek Discovery
MORAb-028	Metastatic melanoma	John Wayne Cancer Institute
MORAb-047	Infectious disease	USAMRIID
MORAb-048		USAMRIID

Morphotek employs its proprietary antibody optimization technology to yield developmental antibodies that possess high-affinity and high-titer characteristics as well as improved effector function.